Harrow (HROW) Acquisitions (2014 - 2015)
Harrow's (HROW) quarterly Acquisitions came in at $3.0 million in Q1 2015, up 7429.27% year-on-year from $39910.9 in Q1 2014, and up 605.04% quarter-over-quarter from -$595000.0 in Q2 2014.
Harrow (HROW) Acquisitions (2014 - 2015) Analysis & Trends
Harrow's Acquisitions history runs 2 years deep, the most recent figure standing at $3.0 million for Q1 2015.
- On a quarterly basis, Acquisitions rose 7429.27% year-over-year to $3.0 million in Q1 2015; TTM through Dec 2015 was $3.0 million, a 572.48% increase from a year earlier, with the FY2025 full-year figure at $4.4 million, changed N/A from the prior year.
- Acquisitions grew to $3.0 million in Q1 2015 per HROW's latest filing, from -$595000.0 in the prior quarter.
- Across five years, Acquisitions topped out at $3.0 million in Q1 2015 and bottomed at -$595000.0 in Q2 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2015 | 3.01 Mn |
| Jun 30, 2014 | -595,000.00 |
| Mar 31, 2014 | -41,000.00 |